Early trial tests new injection for Tough-to-Treat liver cancer
NCT ID NCT06310590
Summary
This early-stage study tested the safety of an experimental injection called NRT6003 in 40 adults with liver cancer that could not be removed by surgery. The main goal was to see if the treatment was safe, while also checking if it could shrink tumors and improve patients' quality of life. The injection delivers a radioactive substance (Yttrium-90) directly to the liver to target cancer cells.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Anhui Provincial Hospital
Hefei, Anhui, China
-
Henan Cancer Hospital
Zhengzhou, Henan, China
-
Hunan Provincial People's Hospital
Changsha, Hunan, China
-
The Affiliated Hospital of Southwest Medical University
Luzhou, Sichuan, China
-
The First Affiliated Hospital of Jinan University
Guangzhou, Guangdong, China
-
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China
-
West China Hospital, Sichuan University
Chengdu, Sichuan, China
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310022, China
-
Zhongda Hospital, Southeast University
Nanjing, Jiangsu, 210009, China
-
Zhongshan Hospital, Fudan University
Shanghai, China
Conditions
Explore the condition pages connected to this study.